SCHEMBL2277413

SCHEMBL2277413

COc1cccc(C(=O)O)n1.[Zn]

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.59
KDM4E B2RXH2 3/20 0.59
ALOX15 P16050 2/20 0.59
TSHR P16473 1/20 0.59
ACMSD Q8TDX5 1/20 0.59
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CTSA P10619 1/20 0.46
ECE1 P42892 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
GNE Q9Y223 1/20 0.42
APLNR P35414 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29527015 0.98 TDP1 (0.61) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL17338 0.98 TDP1 (0.61) TDP1KDM4EALOX15TSHRACMSD
Hydrochloric Acid SCHEMBL29133272 0.96 TDP1 (0.59) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL27691146 0.91 KDM4E (0.53) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL18377809 0.87 ECE1 (0.54) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL31344569 0.85 KDM4E (0.55) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL8866132 0.84 CTSA (0.45) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL13454408 0.83 KDM4E (0.57) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL248517 0.82 CTSA (0.44) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL29858015 0.82 CTSA (0.44) TDP1KDM4EALOX15TSHRACMSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S C/O NOVI A/S, NIELS JERNES VEJ 10 (DK) 2006-07-06 US disclosed
EP-1307189-B1 USE OF HYDROXYETHYLRUTOSIDES FOR TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2006-05-10 EP disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol CHIA, MAVS, C1QBP TDP1 2444/4885KDM4E 430/4885ALOX15 1108/4885
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP TDP1 4320/4885KDM4E 4189/4885ALOX15 699/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP TDP1 4320/4885KDM4E 4189/4885ALOX15 699/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP TDP1 2444/4885KDM4E 430/4885ALOX15 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.